✦ LIBER ✦

Efficacy and Safety of Pegylated Liposomal Doxorubicin in Combination With Bortezomib for Multiple Myeloma: Effects of Adverse Prognostic Factors on Outcome

✍ Scribed by Joan Bladé; Pieter Sonneveld; Jesús F. San Miguel; Heather J. Sutherland; Roman Hajek; Arnon Nagler; Andrew Spencer; Tadeusz Robak; Keith C. Lantz; Sen H. Zhuang; Jean-Luc Harousseau; Robert Z. Orlowski

Book ID: 119936321
Publisher: Elsevier
Year: 2011
Tongue: English
Weight: 193 KB
Volume: 11
Category: Article
ISSN: 2152-2650
DOI: 10.3816/clml.2011.n.005

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCN24 PEGYLATED LIPOSOMAL DOXORUBICIN IN

PCN24 PEGYLATED LIPOSOMAL DOXORUBICIN IN COMBINATION WITH BORTEZOMIB FOR THE TREATMENT OF RELAPSED MULTIPLE MYELOMA—A COST-EFFECTIVENESS STUDY FOR SCOTLAND

✍ CJ Gibbons; K Yong; G Roberts 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB

Extended follow-up of outcome measures i

Extended follow-up of outcome measures in multiple myeloma patients treated on a phase I study with bortezomib and pegylated liposomal doxorubicin

✍ Suzanne E. Biehn; Dominic T. Moore; Peter M. Voorhees; Reynaldo A. Garcia; Mary 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 128 KB

P273 Non-pegylated liposomal doxorubicin

P273 Non-pegylated liposomal doxorubicin in combination with cyclophosphamide and docetaxel as adjuvant therapy for women with high-risk breast cancer. Safety, quality of life, and efficacy analysis of TMC protocol

✍ R. Addeo; L. Montella; G. Cennamo; P. Maione; G. Guerra; M. Bianco; A. Febbraro; 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 41 KB

1p21 deletions are strongly associated w

1p21 deletions are strongly associated with 1q21 gains and are an independent adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma

✍ Chang, H; Qi, X; Jiang, A; Xu, W; Young, T; Reece, D 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 159 KB

1p21 deletions are strongly associated w

1p21 deletions are strongly associated with 1q21 gains and are an independent adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma

✍ Chang, H; Qi, X; Jiang, A; Xu, W; Trieu, Y; Reece, D 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 45 KB

Abnormalities of chromosome 1p/q are hig

Abnormalities of chromosome 1p/q are highly associated with chromosome 13/13q deletions and are an adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma

✍ Ka Lung Wu; Berna Beverloo; Henk M. Lokhorst; Christine M. Segeren; Bronno Van D 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 553 KB